EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Yougui Pills Alleviate Osteoporosis by Inhibiting Mesenchymal Stem Cell ROS Accumulation via the Nrf2/ HO ‐1 Pathway

Jiangyuan Liu iD, Kairui Chen, Jingyuan Wen, Qinghe Zeng, Liangyan Cheng, Qinwen Ge iD, Jiali Chen, Wenhua Yuan iD, Pinger Wang, Luwei Xiao, Hongting Jin iD, Yungang Wu iD

Journal of Cellular and Molecular Medicine · 2026-07 · 30 (14)

DOI: 10.1111/jcmm.71295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 22.07.2026. Verfasst von Jiangyuan Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Orthopaedics and Traumatology of Zhejiang Province, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Osteoporosis, Reactive Oxygen Species, Signal Transduction. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Zhejiang Chinese Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis (OP) is a prevalent skeletal disorder characterized by progressive bone mass loss and deteriorated microarchitecture, in which oxidative stress‐induced mesenchymal stem cell (MSC) dysfunction serves as a core pathogenic mechanism. Yougui Pills (YGPs), a classical traditional Chinese medicine formula, are widely applied in clinical OP management, yet the cellular and molecular mechanisms underlying their anti‐osteoporotic effects remain incompletely defined. This study aimed to elucidate the bone‐protective role of YGPs in OP and explore the underlying mechanism, focusing on oxidative stress modulation in MSCs and the Nrf2/HO‐1 signalling pathway. The bioactive components of YGPs and YGP‐containing serum were characterized via UPLC. In vivo, an ovariectomy (OVX) mouse model was established to evaluate YGPs' effects on bone mass, trabecular microstructure and osteogenesis using micro‐CT, histological and immunohistochemical assays; public GEO datasets were re‐analysed to profile transcriptomic alterations and oxidative stress signatures in OP‐derived MSCs. In vitro, H 2 O 2 was used to induce ROS accumulation and oxidative injury in MSCs, with assessments of cell proliferation, apoptosis, ROS levels, migration and osteogenic differentiation. Network pharmacology and siRNA‐mediated gene silencing were conducted for target prediction and mechanistic validation. In vivo results showed that YGP treatment significantly ameliorated OVX‐induced osteopenia, increased bone mineral density, improved trabecular microstructure, and upregulated osteogenic markers (ALP, OCN, Runx2, COL1A1). Transcriptomic re‐analysis revealed upregulated oxidative stress markers in OP MSCs, consistent with In vitro findings that YGPs attenuated H 2 O 2 ‐triggered ROS overproduction, suppressed apoptosis and ectopic lipid deposition, and enhanced MSC proliferation, migration and osteogenic differentiation. Mechanistically, YGPs activated the Nrf2/HO‐1 signalling axis, while Nrf2 knockdown abrogated YGPs' cytoprotective and pro‐osteogenic effects. In conclusion, YGPs mitigate oxidative stress‐induced MSC dysfunction and promote osteogenesis via the Nrf2/HO‐1 pathway, supporting YGPs as a promising therapeutic candidate for OP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mesenchymal Stem CellsOsteoporosisReactive Oxygen SpeciesSignal TransductionDrugs, Chinese HerbalNF-E2-Related Factor 2Heme Oxygenase-1Membrane ProteinsAnimalsFemaleOxidative StressOsteogenesisMiceCell ProliferationCell DifferentiationApoptosisOvariectomyDisease Models, Animal

Stichwörter der Autor:innen

Nrf2/HO‐1 pathwaymesenchymal stem cellsosteoporosisoxidative stresstraditional chinese medicineyougui pills

Substanzen

Reactive Oxygen SpeciesDrugs, Chinese HerbalNF-E2-Related Factor 2Heme Oxygenase-1Membrane Proteins

Autor:innen und Institutionen

  • Institute of Orthopaedics and Traumatology of Zhejiang Province, Hangzhou, Zhejiang, China.
  • The First College of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
  • The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
  • College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
  • Department of the Orthopedics of TCM, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China.

ORCID-Profile: Jiangyuan Liu, Qinwen Ge, Wenhua Yuan, Hongting Jin, Yungang Wu

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Chinese Medical University

Zitieren

APA

Liu, J., Chen, K., Wen, J., Zeng, Q., Cheng, L., Ge, Q., Chen, J., Yuan, W., Wang, P., Xiao, L., Jin, H., & Wu, Y. (2026). Yougui Pills Alleviate Osteoporosis by Inhibiting Mesenchymal Stem Cell ROS Accumulation via the Nrf2/ HO ‐1 Pathway. Journal of Cellular and Molecular Medicine, 30(14). https://doi.org/10.1111/jcmm.71295

Vancouver

Liu J, Chen K, Wen J, Zeng Q, Cheng L, Ge Q, et al. Yougui Pills Alleviate Osteoporosis by Inhibiting Mesenchymal Stem Cell ROS Accumulation via the Nrf2/ HO ‐1 Pathway. Journal of Cellular and Molecular Medicine. 2026;30(14). doi:10.1111/jcmm.71295

BibTeX
@article{Liu2026,
  author = {Liu, Jiangyuan and Chen, Kairui and Wen, Jingyuan and Zeng, Qinghe and Cheng, Liangyan and Ge, Qinwen and Chen, Jiali and Yuan, Wenhua and Wang, Pinger and Xiao, Luwei and Jin, Hongting and Wu, Yungang},
  title = {Yougui Pills Alleviate Osteoporosis by Inhibiting Mesenchymal Stem Cell ROS Accumulation via the Nrf2/ HO ‐1 Pathway},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  volume = {30},
  number = {14},
  doi = {10.1111/jcmm.71295}
}
Kostenlos starten →